Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences.
Hong SH, Choi KM. · 2020
Read Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. by Hong SH, Choi KM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7013734.txt.
Introduction
Hong and Choi review sarcopenic obesity, the pairing of muscle loss with excess fat, and its link to insulin resistance. Their review appeared in the International Journal of Molecular Sciences. The condition grows commoner worldwide, above all in aging populations. People over 65 already make up 13 percent of the world's population.
Fat stored inside muscle sparks inflammation and oxidative stress. Mitochondria falter, insulin signalling dulls, and muscle wastes further. Less muscle then deepens insulin resistance, a vicious loop. Signals exchanged between muscle and fat, myokines and adipokines, feed the decline. The authors trace the molecular routes connecting the condition to heart disease, type 2 diabetes, and fatty liver disease. Those cardiometabolic diseases are leading killers worldwide. Understanding the loop's mechanics, they argue, is the route to breaking it.
Catalog record
| CREATOR | Hong SH, Choi KM. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences By So-hyeon Hong, Kyung Mook Choi Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms21020494 ABSTRACT Abstract The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease. Keywords: sarcopenic obesity, insulin resistance, cardiometabolic disease 1. INTRODUCTION Aging and obesity are the common public health issues worldwide. People older than 65 years comprise 13% of the global population, and this percentage is increasing at a more rapid rate compared to the percentage of any other age group [1]. With aging, the loss of muscle mass and strength occurs naturally, and is defined as primary sarcopenia. In addition, secondary sarcopenia can develop because of physical inactivity, malnutrition, and diseases, such as neurodegenerative disease, endocrine disease, or malignancy [2]. Reduced muscle mass synergistically accompanies accumulation of fat mass, resulting in sarcopenic obesity [3]. Compared to obesity alone, sarcopenic obesity is associated with a heightened risk of adverse health outcomes, such as disability or impairment, cardiometabolic diseases, other comorbidities, and mortality [4,5,6,7]. Cardiometabolic diseases, including cardiovascular diseases, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD), are the leading causes of death worldwide. Among several risk factors, obesity, excess calorie intake, and low levels of physical activity are the main contributors [8], and insulin resistance (IR) is a common mechanism associated with the disease [9]. IR is the core of the pathophysiological characteristics of sarcopenic obesity. Skeletal muscle is the largest insulin-sensitive tissue and has the largest requirement for postprandial glucose through insulin dependent mechanism. Hence, impaired insulin signaling is commonly observed in sarcopenic obesity [10,11]. In this review, we describe the molecular pathogenesis of sarcopenic obesity with a particular focus on IR. We discuss its roles in cardiometabolic diseases, including atherosclerosis, cardiovascular disease, chronic heart failure, type 2 diabetes mellitus, metabolic syndrome, and NAFLD. 2. SARCOPENIA AND SARCOPENIC OBESITY 2.1. Definition Sarcopenia presents as a decline in skeletal muscle mass and strength. This decline is part of a normal physiological aging process; however, several factors exacerbate this situation, including low physical activity, inadequate nutrition, neurodegenerative disease, and inflammatory conditions. These factors result in increasing frailty and an increased risk of mortality [2,12]. Sarcopenic obesity, a combination of sarcopenia and obesity, is a concurrence of muscle loss and body fat increment. This body composition change brings unchanged or similar body weight or BMI; however, the change shifts toward unfavorable status, including reduced baseline metabolic rate, decreased mitochondrial number and volume, and increased oxidative stress, which exacerbates the vicious cycle [13]. This complex disorder results in a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone [14]. The definition of sarcopenic obesity has not been universally established, and there are various diagnostic criteria for sarcopenia and obesity (Table 1). We previously reported that different definitions of sarcopenia resulted in differential impact on cardiometabolic risk factors. [15]. [Table: Diagnostic criteria for sarcopenic obesity.] 2.2. Molecular Mechanism of Sarcopenic Obesity In sarcopenic obesity, muscle is present as type II muscle fiber atrophy and increased lipid deposition and adipocytes [13,22]. Fast type II muscle fibers switch to slow type I muscle fibers resulting in decreased muscle mass and strength [23]. A decrease in motor neurons and collagen deposition is also observed [24]. 2.2.1. Fat Accumulation Intramyocellular lipid (IMCL) develops when the inflow of fatty acid exceeds the oxidative capacity of skeletal muscle [25]. IMCL predominantly comprises triacylglycerol; however, other lipid intermediates, such as diacylglycerol (DAG), long-chain acetyl coenzyme A, sterol esters, and sphingolipids, including ceramides, also exist [26,27]. These lipids activate PKC and phosphorylate the serine of insulin receptor substrate-1 (IRS-1), interfering with PI3K activation and blocking GLUT4 translocation [28]. GLUT4 is a membrane transporter that transports glucose from blood into myocytes and its dysfunction results in decreased glucose utilization and increased fatty acid oxidation in the mitochondria. Increased fatty acid inflow leads to an increase in the ATP/ADP ratio in the mitochondria, along with a reduced electron transfer chain. This then results in the inhibition of mitochondrial respiration, increase in ROS formation, myocyte toxicity, and finally, development of sarcopenia [29]. Intermyocellular adipose tissue (IMAT) and IMCL secrete myostatin, CCL2, TNF-α, IL-1β, and IL-6, thus inducing IR and lipotoxicity, which is discussed in the next section [30]. Peri-muscular adipose tissue (PMAT) is an ectopic fat deposition surrounding muscle. Increased PMAT enhanced nuclear translocation of the FoxO (forkhead box O) transcription factors and upregulates Atrogin1 and MuRF1, which leads to proteolysis in muscle tissues. The amount of PMAT is correlated with the severity of muscle atrophy [31]. The perilipin family of proteins (PLIN) is embedded in lipid droplets, and functions as a regulator of skeletal muscle lipid metabolism and mitochondrial oxidation [32,33]. PLIN comprises PLIN1 to PLIN5, and PLIN2 and PLIN 5 are predominantly found in muscle tissue [34,35]. Overexpression of PLIN5 in skeletal muscle increases the gene expression involving fatty acid oxidation mediating PPARα and PGC1α [33]. Ablation of PLIN5 results in reduced TAG storage, but increased sphingolipids such as ceramide and sphingomyelin, thus leading to IR in the skeletal muscle [36]. In cultured myocytes, a lipid droplet-associated protein perilipin 2 increases expression of NLRP3 inflammasome, resulting in impaired insulin-stimulated glucose uptake [37]. These results suggest that increased fat accumulation in muscle impairs energy metabolism as well as glucose homeostasis, leading to catabolic status and atrophy of the skeletal muscle. 2.2.2. Inflammation In sarcopenic obesity, adipocytes are accumulated not only in muscle tissue, but also in other organs. Increased adipose tissue secretes proinflammatory cytokines such as TNF-α, IL-6, and IL-1, and this promotes infiltration of inflammatory cells, including macrophages. In adipose tissue from lean subjects, approximately 10% of cells stained positive for macrophages, but in obese subjects, this number increased to up to 50% [38]. The infiltrated macrophages in muscle tissue present adipocyte-derived antigens and activate antigen-specific CD4+ T cells [39]. Macrophages also change the phenotype from M2 to M1, which releases proinflammatory molecules such as TNF-α, IL-1β, IL-6, and MCP-1/CCL2 [40,41]. These cytokines induce muscle atrophy by increasing apoptosis and upregulating proteosomal decay of filament proteins [42]. Using a proteomics approach, the cellular pathways activating macrophages are associated with sterile inflammation, which is distinct from classical activation by bacterial or viral infection [43,44]. In obesity-induced activation of macrophages, CD38, CD319, and CD274, are derived from the cell surface and only approximately 5% of the cell surface protein expression patterns overlap [43]. However, macrophages regulate inflammation in adipose tissue, and have autophagic functions whereby they prevent proinflammatory M1 macrophage-polarization by delivering